Silicon Investor (SI) -- The First Internet Community

Piotroski F-Score: Exelixis (EXEL) has a strong Piotroski F-Score of 8.00 out of 9 , and some sources even indicate a perfect score of 9 . This suggests excellent financial health.
PEG Ratio: Exelixis (EXEL) has a PEG Ratio of approximately 0.78 to 0.88 . A PEG ratio of less than 1 generally indicates that a stock may be undervalued relative to its earnings growth.

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Fundamental Value Investing -- Ignore unavailable to you. Want to Upgrade?

To: bruwin who wrote (4690)	7/3/2025 7:53:45 PM
From: E_K_S	1 Recommendation Recommended By bruwin Read Replies (1) \| Respond to of 4719

Wow ! Nice find Exelixis Inc (EXEL) 46.15 +1.85 (+4.18%) (close to an All Time High; $12 Billion markt cap) Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the company's flagship molecule, which is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET. As of early July 2025, here's the information on Exelixis Inc (EXEL)'s F-score and PEG ratio: Piotroski F-Score: Exelixis (EXEL) has a strong Piotroski F-Score of 8.00 out of 9, and some sources even indicate a perfect score of 9. This suggests excellent financial health. PEG Ratio: Exelixis (EXEL) has a PEG Ratio of approximately 0.78 to 0.88. A PEG ratio of less than 1 generally indicates that a stock may be undervalued relative to its earnings growth. It's not often you find a stock w/ a 8-9 F-score AND PEG <=1.0. This shows nice growth and a solid balance sheet, On my watch list for 2025 new Buy candidates